Oxygen-ozone therapy as support and palliative therapy in 50 cancer patients with fatigue - A short report

U Tirelli; C Cirrito; M Pavanello; L Del Pup; A Lleshi; M Berretta

doi:10.26355/eurrev_201811_16432

Oxygen-ozone therapy as support and palliative therapy in 50 cancer patients with fatigue - A short report

U Tirelli, C Cirrito, M Pavanello, L Del Pup, A Lleshi, M Berretta

Research output: Contribution to journal › Article › peer-review

Abstract

OBJECTIVE: Fatigue may be cause by all cancer treatments, maybe because the tissue damage or the build-up of dead cells derived products.

PATIENTS AND METHODS: At the Mede Clinic in Sacile, Pordenone, Italy, from February 2016 to May 2018 we studied 50 patients with cancer and fatigue (15 with breast cancer, 12 with lung cancer, 11 with colon cancer, 5 with renal cancer, 3 with prostate cancer, 2 with melanoma and 2 hepatocellular carcinoma). Patients were treated with Auto Hemotransfusion (GAE) according to the SIOOT (Scientific Society of Oxygen Ozone Therapy) protocols, two times a week for one month and then twice monthly as maintenance therapy.

RESULTS: Nineteen of them were undergoing neoplastic treatment, 10 had already ended the cancer therapy and 21 were in a palliative setting. The Fatigue Severity Scale was used to assess the extent of fatigue in patients, in order to estimate the severity of the symptom with a score from 1 to 7. No side effects were found, and 35 patients (70%) achieved a significant improvement (> 50%) of the symptoms.

CONCLUSIONS: Our preliminary data demonstrate that ozone therapy is a valid supportive therapy for fatigue in cancer patients, both during cancer therapy and in a palliative setting with no significant side effects.

Original language	English
Pages (from-to)	8030-8033
Number of pages	4
Journal	European Review for Medical and Pharmacological Sciences
Volume	22
Issue number	22
DOIs	https://doi.org/10.26355/eurrev_201811_16432
Publication status	Published - Nov 2018

Access to Document

10.26355/eurrev_201811_16432

Cite this

@article{1d0ad69ea52d452e8a9d0b87549c36ac,

title = "Oxygen-ozone therapy as support and palliative therapy in 50 cancer patients with fatigue - A short report",

abstract = "OBJECTIVE: Fatigue may be cause by all cancer treatments, maybe because the tissue damage or the build-up of dead cells derived products.PATIENTS AND METHODS: At the Mede Clinic in Sacile, Pordenone, Italy, from February 2016 to May 2018 we studied 50 patients with cancer and fatigue (15 with breast cancer, 12 with lung cancer, 11 with colon cancer, 5 with renal cancer, 3 with prostate cancer, 2 with melanoma and 2 hepatocellular carcinoma). Patients were treated with Auto Hemotransfusion (GAE) according to the SIOOT (Scientific Society of Oxygen Ozone Therapy) protocols, two times a week for one month and then twice monthly as maintenance therapy.RESULTS: Nineteen of them were undergoing neoplastic treatment, 10 had already ended the cancer therapy and 21 were in a palliative setting. The Fatigue Severity Scale was used to assess the extent of fatigue in patients, in order to estimate the severity of the symptom with a score from 1 to 7. No side effects were found, and 35 patients (70%) achieved a significant improvement (> 50%) of the symptoms.CONCLUSIONS: Our preliminary data demonstrate that ozone therapy is a valid supportive therapy for fatigue in cancer patients, both during cancer therapy and in a palliative setting with no significant side effects.",

author = "U Tirelli and C Cirrito and M Pavanello and {Del Pup}, L and A Lleshi and M Berretta",

year = "2018",

month = nov,

doi = "10.26355/eurrev_201811_16432",

language = "English",

volume = "22",

pages = "8030--8033",

journal = "European Review for Medical and Pharmacological Sciences",

issn = "1128-3602",

publisher = "Verduci Editore",

number = "22",

}

TY - JOUR

T1 - Oxygen-ozone therapy as support and palliative therapy in 50 cancer patients with fatigue - A short report

AU - Tirelli, U

AU - Cirrito, C

AU - Pavanello, M

AU - Del Pup, L

AU - Lleshi, A

AU - Berretta, M

PY - 2018/11

Y1 - 2018/11

N2 - OBJECTIVE: Fatigue may be cause by all cancer treatments, maybe because the tissue damage or the build-up of dead cells derived products.PATIENTS AND METHODS: At the Mede Clinic in Sacile, Pordenone, Italy, from February 2016 to May 2018 we studied 50 patients with cancer and fatigue (15 with breast cancer, 12 with lung cancer, 11 with colon cancer, 5 with renal cancer, 3 with prostate cancer, 2 with melanoma and 2 hepatocellular carcinoma). Patients were treated with Auto Hemotransfusion (GAE) according to the SIOOT (Scientific Society of Oxygen Ozone Therapy) protocols, two times a week for one month and then twice monthly as maintenance therapy.RESULTS: Nineteen of them were undergoing neoplastic treatment, 10 had already ended the cancer therapy and 21 were in a palliative setting. The Fatigue Severity Scale was used to assess the extent of fatigue in patients, in order to estimate the severity of the symptom with a score from 1 to 7. No side effects were found, and 35 patients (70%) achieved a significant improvement (> 50%) of the symptoms.CONCLUSIONS: Our preliminary data demonstrate that ozone therapy is a valid supportive therapy for fatigue in cancer patients, both during cancer therapy and in a palliative setting with no significant side effects.

AB - OBJECTIVE: Fatigue may be cause by all cancer treatments, maybe because the tissue damage or the build-up of dead cells derived products.PATIENTS AND METHODS: At the Mede Clinic in Sacile, Pordenone, Italy, from February 2016 to May 2018 we studied 50 patients with cancer and fatigue (15 with breast cancer, 12 with lung cancer, 11 with colon cancer, 5 with renal cancer, 3 with prostate cancer, 2 with melanoma and 2 hepatocellular carcinoma). Patients were treated with Auto Hemotransfusion (GAE) according to the SIOOT (Scientific Society of Oxygen Ozone Therapy) protocols, two times a week for one month and then twice monthly as maintenance therapy.RESULTS: Nineteen of them were undergoing neoplastic treatment, 10 had already ended the cancer therapy and 21 were in a palliative setting. The Fatigue Severity Scale was used to assess the extent of fatigue in patients, in order to estimate the severity of the symptom with a score from 1 to 7. No side effects were found, and 35 patients (70%) achieved a significant improvement (> 50%) of the symptoms.CONCLUSIONS: Our preliminary data demonstrate that ozone therapy is a valid supportive therapy for fatigue in cancer patients, both during cancer therapy and in a palliative setting with no significant side effects.

U2 - 10.26355/eurrev_201811_16432

DO - 10.26355/eurrev_201811_16432

M3 - Article

SN - 1128-3602

VL - 22

SP - 8030

EP - 8033

JO - European Review for Medical and Pharmacological Sciences

JF - European Review for Medical and Pharmacological Sciences

IS - 22

ER -

Oxygen-ozone therapy as support and palliative therapy in 50 cancer patients with fatigue - A short report

Abstract

Access to Document

Fingerprint

Cite this